Dual targeting single arrow: Neutrophil-targeted sialic acid-modified nanoplatform for treating comorbid tumors and rheumatoid arthritis

Lai, Xiaoxue; Wang, Shuo; Hu, Miao; Sun, Yiming; Chen, Meng; Li, Mengyang; Li, Gang; Deng, Yihui

doi:10.1016/j.ijpharm.2021.121022

Cited by 6 publications

(4 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The particle size, PDI, and zeta potential of BUD- l -Arg@PSA were measured using a NICOMP 380 submicron particle sizer (CA, USA). The morphology of BUD- l -Arg@PSA was observed by TEM (JEM-2100, JEOL Co., Ltd., Tokyo, Japan) and AFM (Nanoscope V, Bruker, USA) . The EE% of BUD- l -Arg@PSA was determined by cation-exchange resin microcolumn centrifugation .…”

Section: Methodsmentioning

confidence: 99%

Minimalist Nanocomplex with Dual Regulation of Endothelial Function and Inflammation for Targeted Therapy of Inflammatory Vascular Diseases

Wang

Lai

et al. 2023

ACS Nano

Self Cite

View full text Add to dashboard Cite

Vascular disorders, characterized by vascular endothelial dysfunction combined with inflammation, are correlated with numerous fatal diseases, such as coronavirus disease-19 and atherosclerosis. Achieving vascular normalization is an urgent problem that must be solved when treating inflammatory vascular diseases. Inspired by the vascular regulatory versatility of nitric oxide (NO) produced by endothelial nitric oxide synthase (eNOS) catalyzing l-arginine (l-Arg), the eNOS-activating effects of l-Arg, and the powerful anti-inflammatory and eNOS-replenishing effects of budesonide (BUD), we constructed a bi-prodrug minimalist nanoplatform co-loaded with BUD and l-Arg via polysialic acid (PSA) to form BUD-l-Arg@PSA. This promoted vascular normalization by simultaneously regulating vascular endothelial dysfunction and inflammation. Mediated by the special affinity between PSA and E-selectin, which is highly expressed on the surface of activated endothelial cells (ECs), BUD-l-Arg@PSA selectively accumulated in activated ECs, targeted eNOS expression and activation, and promoted NO production. Consequently, the binary synergistic regulation of the NO/eNOS signaling pathway occurred and improved vascular endothelial function. NO-induced nuclear factor-kappa B alpha inhibitor (IκBα) stabilization and BUD-induced nuclear factor-kappa B (NF-κB) response gene site occupancy achieved dual-site blockade of the NF-κB signaling pathway, thereby reducing the inflammatory response and inhibiting the infiltration of inflammation-related immune cells. In a renal ischemia-reperfusion injury mouse model, BUD-l-Arg@PSA reduced acute injury. In an atherosclerosis mouse model, BUD-l-Arg@PSA decreased atherosclerotic plaque burden and improved vasodilation. This represents a revolutionary therapeutic strategy for inflammatory vascular diseases.

show abstract

Section: Methodsmentioning

confidence: 99%

Minimalist Nanocomplex with Dual Regulation of Endothelial Function and Inflammation for Targeted Therapy of Inflammatory Vascular Diseases

Wang

Lai

et al. 2023

ACS Nano

Self Cite

View full text Add to dashboard Cite

show abstract

“…4a). 1,30,31,43 Our objective was to develop a novel type of nanomedicines able to treat diseases with an inflammatory background such as cancer and auto-immune diseases. MTX was selected as this drug is not only the first-line conventional drug for RA but also one of the first generation anticancer drugs prescribed for human cancers.…”

Section: Ph-and Glutathione (Gsh) Responsive Release Properties Of Na...mentioning

confidence: 99%

“…Note that RA is frequently accompanied by other diseases such as cancer 32 that can affect all body organs with, however, to date, no effective available therapy targeting simultaneous cancer and RA. 30–32 This USPIO@MIL nanovector and drug loaded analogues possess low cytotoxicity while their biodegradability was demonstrated through their internalization in macrophages and intracellular fate monitored by TEM. Remarkably, the stimuli-responsive drug release properties of USPIO@MIL/Dox (and also USPIO@MIL/MTX to a lesser extent) confer to these nanovectors a high anti-tumoral and anti-inflammatory capability.…”

Section: Introductionmentioning

confidence: 99%

“…Two complementary anti-cancer and antiinflammatory drugs (either doxorubicin (Dox) and methotrexate (MTX)) were encapsulated with a high drug loading in this bimodal nanovector to synergistically target both malignant cells and tumor inflammatory components. Indeed, Dox, a widely used anticancer drug, has also shown its capacity to induce apoptosis of inflammatory neutrophils, 30,31 while MTX is not only a chemotherapy agent but also the first-line conventional drug for rheumatoid arthritis (RA). Our objective was thus to design a novel type of nanomedicine for the treatment of chronic inflammatory diseases such as RA.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Hierarchical superparamagnetic metal–organic framework nanovectors as anti-inflammatory nanomedicines

et al. 2023

View full text Add to dashboard Cite

show abstract

Nanoformulation-assisted microneedle transdermal drug delivery system: An innovative platform enhancing rheumatoid arthritis treatment

Wendong,

Xingxing,

Xianze

et al. 2024

Biomedicine & Pharmacotherapy

View full text Add to dashboard Cite

Dual targeting single arrow: Neutrophil-targeted sialic acid-modified nanoplatform for treating comorbid tumors and rheumatoid arthritis

Cited by 6 publications

References 44 publications

Minimalist Nanocomplex with Dual Regulation of Endothelial Function and Inflammation for Targeted Therapy of Inflammatory Vascular Diseases

Minimalist Nanocomplex with Dual Regulation of Endothelial Function and Inflammation for Targeted Therapy of Inflammatory Vascular Diseases

Hierarchical superparamagnetic metal–organic framework nanovectors as anti-inflammatory nanomedicines

Nanoformulation-assisted microneedle transdermal drug delivery system: An innovative platform enhancing rheumatoid arthritis treatment

Contact Info

Product

Resources

About